In a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies, with a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors surrounding Taysha Gene Therapies. One of the primary reasons is the initiation of the pivotal study for TSHA-102, which is on schedule for the fourth quarter of 2025. The study’s design is considered favorable and relatively low-risk, supported by strong clinical data from the REVEAL study, where all participants met the response criteria. This positive outlook is further reinforced by the company’s financial health, with a substantial cash reserve following a significant financing round.
Additionally, Taysha plans to release updated results from the REVEAL study, which will include follow-up data from the high-dose cohort. This data is expected to demonstrate how achieving certain milestones translates into improvements in activities of daily living. These developments contribute to the confidence in Taysha’s potential, justifying the Buy rating and maintaining the price target of $8.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.